We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Compugen (CGEN) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Compugen (CGEN - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Compugen is one of 913 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Compugen is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CGEN's full-year earnings has moved 3.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, CGEN has returned 73.2% so far this year. In comparison, Medical companies have returned an average of 5.2%. This shows that Compugen is outperforming its peers so far this year.
Another stock in the Medical sector, Envoy Medical, Inc. (COCH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 13.5%.
In Envoy Medical, Inc.'s case, the consensus EPS estimate for the current year increased 3.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Compugen belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual stocks and currently sits at #160 in the Zacks Industry Rank. This group has gained an average of 9.9% so far this year, so CGEN is performing better in this area.
Envoy Medical, Inc., however, belongs to the Medical - Instruments industry. Currently, this 77-stock industry is ranked #105. The industry has moved -7.2% so far this year.
Compugen and Envoy Medical, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Compugen (CGEN) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Compugen (CGEN - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Compugen is one of 913 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Compugen is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CGEN's full-year earnings has moved 3.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, CGEN has returned 73.2% so far this year. In comparison, Medical companies have returned an average of 5.2%. This shows that Compugen is outperforming its peers so far this year.
Another stock in the Medical sector, Envoy Medical, Inc. (COCH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 13.5%.
In Envoy Medical, Inc.'s case, the consensus EPS estimate for the current year increased 3.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Compugen belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual stocks and currently sits at #160 in the Zacks Industry Rank. This group has gained an average of 9.9% so far this year, so CGEN is performing better in this area.
Envoy Medical, Inc., however, belongs to the Medical - Instruments industry. Currently, this 77-stock industry is ranked #105. The industry has moved -7.2% so far this year.
Compugen and Envoy Medical, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.